First-line inotuzumab ozogamicin plus R-CVP evaluated in anthracycline-unfit DLBCL patients

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Jun 19 / Springer Healthcare

First-line inotuzumab ozogamicin plus R-CVP evaluated in anthracycline-unfit DLBCL patients

University of Manchester and the Christie Hospital, UK

Haematology EHA-2020

Description

Elizabeth Phillips describes their phase 2 trial showing that the combination of inotuzumab ozogamicin and R-CVP is efficacious for certain subgroups of treatment-naïve, R-CHOP-ineligible patients with diffuse large B-cell lymphoma, and outlines the next steps to improve treatment outcomes.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.